12:00 AM
May 03, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ART-123: Completed Phase IIb enrollment

Artisan completed enrollment of 750 sepsis patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating 6 mg/mL injectable ART-123. The product is approved for the...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >